SOUTH SAN FRANCISCO, Calif., Aug. 21, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the BioCentury and Thomson Reuters 19th Annual Newsmakers in the Biotech Industry 2012 Conference in New York on Friday, September 7 at 11:00 a.m. ET (8:00 a.m. PT).
Donald J. Santel, Chief Executive Officer of Hyperion, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion Therapeutics is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders and hepatic encephalopathy.